We tested the fl uoroquinolone susceptibility of 499 Salmonella enterica isolates collected from travelers returning to Finland during [2003][2004][2005][2006][2007]. Among isolates from travelers to Thailand and Malaysia, reduced fl uoroquinolone susceptibility decreased from 65% to 22% (p = 0.002). All isolates showing nonclassical quinolone resistance were from travelers to these 2 countries.
We tested the fl uoroquinolone susceptibility of 499 Salmonella enterica isolates collected from travelers returning to Finland during [2003] [2004] [2005] [2006] [2007] . Among isolates from travelers to Thailand and Malaysia, reduced fl uoroquinolone susceptibility decreased from 65% to 22% (p = 0.002). All isolates showing nonclassical quinolone resistance were from travelers to these 2 countries.
F luoroquinolones are the most commonly used antimicrobial agents for the treatment of salmonellosis in adult patients (1) . The proportion of nontyphoidal strains of Salmonella enterica with reduced fl uoroquinolone susceptibility has increased during recent years in many countries (1) (2) (3) . In Finland, fl uoroquinolone susceptibility of salmonella has been surveyed since 1995 by analyzing isolates from patients who acquired the disease either at home or abroad. From 1995 through 2004, reduced fl uoroquinolone susceptibility (MIC >0.125 μg/mL) increased signifi cantly (4.0% to 39%) among all foreign Salmonella isolates (3, 4) . The increase was most prominent among isolates from Southeast Asia, especially Thailand (4).
Until 2002, all Salmonella isolates worldwide with reduced ciprofl oxacin susceptibility were uniformly resistant to nalidixic acid (3-5); i.e., they exhibited the conventional quinolone resistance phenotype. In 2003, we identifi ed Salmonella isolates that showed reduced susceptibility to ciprofl oxacin but were either susceptible (MIC <32 μg/mL) or only low-level resistant (MIC = 32 μg/mL) to nalidixic acid. All Salmonella isolates with this nonclassical quinolone resistance phenotype were from travelers returning from Thailand or Malaysia (6) . We undertook this study to survey the recent incidence of reduced fl uoroquinolone susceptibility among nontyphoidal strains of S. enterica acquired by Finnish travelers abroad and to defi ne the epidemiology of the nonclassical quinolone-resistant Salmonella population.
The Study
Our study included 499 S. enterica isolates collected during 2003-2007 from Finnish travelers returning from abroad; due to a technical error, in 2004 only 99 foreign Salmonella isolates were sent to us from the National Salmonella Reference Center. The fi rst 100 foreign Salmonella isolates identifi ed during January of each year were collected. An isolate was designated to be of foreign origin if the patient had reported travel abroad during the month before the specimen was obtained. Epidemiologic information regarding travel destination was collected from the forms accompanying each isolate.
MICs of ciprofl oxacin and nalidixic acid for the isolates were determined by using plate agar dilution (7). The MIC breakpoint value for reduced ciprofl oxacin susceptibility was chosen as >0.125 μg/mL on the basis of earlier publications (4, 5, 8) . The breakpoints for nalidixic acid were 16 μg/mL for susceptibility and 32 μg/mL for resistance, according to Clinical and Laboratory Standards Institute guidelines (7) .
Pulsed-fi eld gel electrophoresis (PFGE) was performed using PulseNet standardized protocol with few modifi cations (9) . We considered any difference between 2 profi les to be suffi cient to distinguish 2 different PFGE profi les.
Data concerning the number of travelers from Finland to countries of interest (i.e., countries with Salmonella isolates showing reduced fl uoroquinolone susceptibility) during the study months were received from Statistics Finland (www.stat.fi ). Susceptibility data were analyzed by using WHONET5.4. For statistical analyses, we summarized data on the basis of the number and proportion of Salmonella isolates with reduced fl uoroquinolone susceptibiity. The trend over years was analyzed using a logistic regression model with year as a covariate; p<0.05 was considered signifi cant. Statistical analyses were performed using SAS for Windows version 9.1.3 (SAS Institute Inc., Cary, NC, USA).
Of the 499 S. enterica isolates collected, 227 came from travelers returning to Finland from Thailand or Malaysia (Table) . Among all Salmonella isolates, reduced fl uoroquinolone susceptibility decreased from 48% in 2003 to 34% in 2007 (p = 0.029). Among the isolates from Thailand and Malaysia, the decrease was 65% to 32% (p = 0.002) (Figure 1, panel A) (Figure 1, panel B) .
The nonclassical quinolone resistance phenotype fi rst appeared in 2003. Subsequently, 36 Salmonella isolates showing this resistance pattern have been identifi ed. From 2003 through 2007, the yearly proportions of Salmonella isolates showing the nonclassical quinolone resistance phenotype were 9%, 8%, 2%, 5%, and 12%, respectively; there was no signifi cant difference from year to year (p = 0.720). Among the isolates from Thailand and Malaysia, the nonclassical quinolone resistance varied; however, the difference from year to year was not signifi cant (p = 0.878) (Figure 1, panel B) .
The 499 Salmonella isolates in this study were collected from travelers returning from 43 different countries; isolates with reduced ciprofl oxacin susceptibility were collected from travelers returning from 18 countries (Table) . All 36 isolates showing the nonclassical resistance phenotype were from Thailand or Malaysia; 47% of the isolates showing the conventional quinolone resistance phenotype were from these 2 countries.
The nonclassical quinolone resistance phenotype was found in 7 different serovars, of which S. enterica serovar Corvallis and S. enterica serovar Stanley were the most prevalent; among the conventional quinolone resistance phenotype, S. enteritidis and S. virchow were the most prevalent. The 36 isolates belonging to the nonclassical phenotype were distinguished by PFGE to 16 different PFGE patterns (Figure 2 ).
Conclusions
Reduced fl uoroquinolone susceptibility among nontyphoidal strains of S. enterica among travelers from Finland, as a whole, decreased signifi cantly during the study period, 2003-2007 after having constantly increased for several (Table) . In addition, after the emergence of the nonclassical quinolone resistance phenotype among S. enterica in Thailand and Malaysia, these isolates have persisted in that area. Our study shows a minor variation in the proportion of this resistance phenotype among the whole quinoloneresistant population. For example, in 2005 the proportion of the nonclassical phenotype isolates was only 6%, but in that year, the proportion of all isolates with reduced ciprofl oxacin susceptibility was small. This result is most likely due to the collection of the foreign isolates soon after the tsunami catastrophe in December 2004; travelers from Finland took >20% fewer trips to Thailand in 2005 than in 2004 (Table) .
All of the Salmonella isolates showing the nonclassical quinolone resistance phenotype were from Thailand or Malaysia. Despite this geographic stability, isolates of the nonclassical phenotype were nonclonal, as shown by PFGE. These fi ndings provoke the question of whether the emergence, persistence, and confi nement of those isolates in this area might have something to do with the living conditions of the residing population. In 2007, the proportion of the nonclassical phenotype surpassed that of the conventional phenotype for the fi rst time (20% vs. 12%; Figure 1, panel  B) . This increase in nonclassical phenotypes may be an emerging trend that needs to be under close surveillance.
The nonclassical quinolone-resistant population may prove hard to identify in those microbiological laboratories that use only nalidixic acid to screen for reduced fl uoroquinolone susceptibility in salmonella isolates. It is to be expected that this screening approach may fail due to susceptibility or only low-level resistance to nalidixic acid in these isolates (10) (11) (12) . Isolates collected from travelers returning from Thailand or Malaysia should especially be examined for fl uoroquinolone susceptibility because nalidixic acid screening test results may no longer be predictive of fl uoroquinolone resistance. At the present time, the nonclassical phenotype appears to be mainly confi ned to Thailand and Malaysia (10, 11) , but given the continuous increase in global travel, these isolates may emerge in other parts of the world.
